TrialAmerican journal of hematology2010

Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

Giovanni Barosi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.